BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

GlobeImmune, Inc. 

1450 Infinite Drive

Louisville  Colorado  80027  U.S.A.
Phone: 303-625-2700 Fax: 303-625-2710


SEARCH JOBS

View Clinical Trials from BioPharm Insight









 Company News
GlobeImmune, Inc. (GBIM) Announces Closing Of Initial Public Offering And Full Exercise Of Underwriter's Overallotment Option 7/9/2014 9:05:06 AM
Colorado's GlobeImmune, Inc. (GBIM) Prices IPO At $10 A Share, Below Expectations 7/2/2014 6:07:32 AM
Louisville's GlobeImmune, Inc. Reduces Size Of Proposed IPO 5/22/2014 7:51:38 AM
Pancreatic Cancer Biotech GlobeImmune, Inc. Sets Terms For $35 Million In Second IPO Attempt 4/30/2014 7:03:37 AM
Colorado-Based GlobeImmune, Inc. Gives IPO A Second Shot, Aims For $35 Million 3/18/2014 7:36:16 AM
Biotech GlobeImmune, Inc. Withdraws $60 Million IPO 11/1/2013 7:44:57 AM
GlobeImmune, Inc. Offers IPO Details 9/6/2012 8:26:34 AM
GlobeImmune, Inc. Files Paperwork for $69 Million IPO 7/3/2012 6:21:39 AM
GlobeImmune, Inc.'s GI-4000 in Combination With Gemcitabine Following Surgery Shows Evidence of an Improvement in Survival in a Phase 2b Clinical Trial With Ras Mutation Positive Pancreas Cancer 6/27/2012 9:09:15 AM
GlobeImmune, Inc. Initiates Phase 1 Clinical Trial of GI-6301 in Brachyury Expressing Cancers 2/8/2012 11:43:28 AM
123456